This segment focuses on the development of innovative therapies for Parkinson's Disease (PD) and related disorders. Research and development efforts are centered on IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, designed to treat PD and its early gastrointestinal complications such as dysphagia and neurogenic constipation. The therapeutic approach aims to address the underlying mechanisms of PD by targeting protein kinases involved in disease progression. Clinical trials are underway to evaluate the safety and efficacy of IkT-148009 in improving motor and non-motor symptoms of PD, with the goal of enhancing the quality of life for patients. Future opportunities include expanding the application of IkT-148009 to other neurodegenerative diseases and exploring combination therapies to maximize patient outcomes.

The Pulmonary Arterial Hypertension (PAH) program is dedicated to advancing IkT-001, a prodrug of Imatinib, into late-stage clinical trials. This segment focuses on minimizing gastrointestinal side effects associated with Imatinib through the development of a novel prodrug formulation. Research and development activities include preclinical studies to optimize drug delivery and efficacy, as well as clinical trials to assess the safety and effectiveness of IkT-001 in treating PAH. The therapeutic approach aims to improve pulmonary hemodynamics and exercise capacity in PAH patients, addressing a significant unmet medical need. Future opportunities involve exploring combination therapies with existing PAH treatments and expanding the application of IkT-001 to other pulmonary vascular diseases.